Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:09 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,017 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Infection Clear all
Not listed Phase 2 Interventional

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

NCT00057369
View directory record Official record
Conditions
Bacteremia
Interventions
dalbavancin
Drug
Lead sponsor
Vicuron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 11:09 PM EST
Terminated Not applicable Interventional

Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

NCT02890875
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Ethanol lock, Heparin lock
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Nov 3, 2026, 11:09 PM EST
Enrolling by invitation No phase listed Observational

STUDY00015328: Sepsis Endotypes

NCT03146546
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2020 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 1 Interventional

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

NCT00004494
View directory record Official record
Conditions
Sepsis, Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
Interventions
vasoactive intestinal peptide
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Northport, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 3, 2026, 11:09 PM EST
Completed No phase listed Observational

Methionine Metabolism in Parenterally Fed Pediatric Sepsis

NCT01891682
View directory record Official record
Conditions
Sepsis, Critical Illness
Interventions
Observational
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
1 Month to 19 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Nov 3, 2026, 11:09 PM EST
Completed Not applicable Interventional

Sepsis, Severe Sepsis and Septic Shock Detection by Breath Analysis

NCT03497182
View directory record Official record
Conditions
Sepsis
Interventions
Breath sample collection
Device
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 4 Interventional

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

NCT02660346
View directory record Official record
Conditions
Bacteremia
Interventions
Daptomycin, Vancomycin, Ceftaroline
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Nov 3, 2026, 11:09 PM EST
Not yet recruiting No phase listed Observational

Duke Virtual IntEgrated Workflow

NCT07406074
View directory record Official record
Conditions
Falls Injury, Readmission Rates, CLABSI - Central Line Associated Bloodstream Infection, Catheter Associated Urinary Tract Infection, Hospital Acquired Pressure Injury, Venous Thromboembolism (VTE), Nurses, Satisfaction, Patient, Length of Stay
Interventions
Co-Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 3, 2026, 11:09 PM EST
Terminated Phase 3 Interventional

Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

NCT00016523
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Respiratory Distress Syndrome (RDS), Sepsis, Pneumonia, Hypertension, Pulmonary
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 120 Hours
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Nov 3, 2026, 11:09 PM EST
Not listed Phase 2 Interventional

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

NCT01782170
View directory record Official record
Conditions
Gingivitis, Investigation of Biological Markers of Inflammation
Interventions
Iocide Oral Rinse, Placebo
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Nov 3, 2026, 11:09 PM EST
Withdrawn Not applicable Interventional

Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

NCT01063010
View directory record Official record
Conditions
Septic Shock
Interventions
Bevacizumab, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Camden, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 1 Interventional

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

NCT00002946
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
penclomedine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Nov 3, 2026, 11:09 PM EST
Completed No phase listed Observational

T2Bacteria Panel Pivotal Study

NCT02535468
View directory record Official record
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
2,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Nov 3, 2026, 11:09 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Implementation Program to Improve CHG Bathing Compliance

NCT03898115
View directory record Official record
Conditions
Central Line-associated Bloodstream Infection (CLABSI)
Interventions
CHG Education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 3 Interventional

Voriconazole to Treat Fungal Infections

NCT00001940
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 2 Interventional Results available

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

NCT01526889
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions
LFG316, Conventional Therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Golden, Colorado • Marietta, Georgia • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 3, 2026, 11:09 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Inflammation in Methamphetamine and STIs (IMSTI)

NCT05162391
View directory record Official record
Conditions
Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia
Interventions
Contingency Management
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 3, 2026, 11:09 PM EST
Not listed No phase listed Observational

POC SPLA2-IIA as a Biomarker for Sepsis and Septic Shock

NCT03953404
View directory record Official record
Conditions
Sepsis
Interventions
SPLA2-IIA
Diagnostic Test
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
450 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Nov 3, 2026, 11:09 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Risk Factors, Costs, and Impacts of ED Boarding

NCT07532564
View directory record Official record
Conditions
Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30,486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Nov 3, 2026, 11:09 PM EST
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 1 Interventional

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Nov 3, 2026, 11:09 PM EST
Completed Phase 3 Interventional

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248
View directory record Official record
Conditions
Sepsis, Bacteremia, Fungemia
Interventions
MBI 226
Drug
Lead sponsor
BioWest Therapeutics Inc
Industry
Eligibility
16 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lake Bluff, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Nov 3, 2026, 11:09 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers in Infection

NCT02545478
View directory record Official record
Conditions
Sepsis, Infection, Inflammation
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 3, 2026, 11:09 PM EST